Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

Fig. 3

Biocompability evaluation, drug loading and release. (a) CCK8 assay to evaluate the cell viability of HUVEC cells after incubation with different concentrations of NPs for 24 h. (b) Hemolysis test results of NPs after incubation with 5% of the mice’s RBC suspension at 37 ℃ for 4 h. PBS was used as a negative control and water was used as a positive control. (c, d) Representative fluorescence image and quantization of RAW 264.7 after incubation with different NPs for 2 h at 37 ℃ (UiO-66 = 0.1 mg/ml). (e) LE and EE of NHWD-870. (f) Cumulative release rates of NHWD-870 from MCM@UN or UN, respectively, at different pH values (7.4 and 5.0). Data are presented as the mean ± SD (n = 3), ***P < 0.001

Back to article page